US Patent 8,653,094: Telotristat Crystalline-Form and Peripheral Serotonin Treatment Patent Analysis

US Patent 8,653,094 protects methods of treating peripheral-serotonin-mediated diseases with crystalline telotristat ethyl and specified telotristat ethyl salts, including the hippurate and succinate forms. The patent is directed primarily to the active pharmaceutical ingredient's solid-state form and therapeutic use, not to tablet excipients, dosage strength, manufacturing equipment, or a broad class of serotonin inhibitors.

The patent is relevant to Xermelo (telotristat ethyl/telotristat etiprate), marketed by Lexicon Pharmaceuticals in the United States and commercialized internationally by Ipsen. Its principal commercial value is the potential to block a generic product that uses the claimed crystalline active ingredient or salt for the claimed peripheral-serotonin indications.

What compound does US Patent 8,653,094 protect?

The patent covers a specific stereochemically defined telotristat compound:

(S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate
The free-base crystalline form
Pharmaceutically acceptable crystalline salts
Specifically, hippurate and succinate salts

The compound is telotristat ethyl. Telotristat etiprate is the hippurate salt form used in the Xermelo product nomenclature and regulatory materials.

The patent does not claim every telotristat-related compound. Its claims require the exact molecular structure, the relevant stereochemistry, and a crystalline form or crystalline salt.

What are the independent legal limitations of claim 1?

Claim 1 has four central limitations:

Limitation	Scope
Treatment method	Administration to a patient in need of treatment or management
Disease mechanism	Disease or disorder mediated by peripheral serotonin
Active compound	Exact crystalline telotristat ethyl compound or pharmaceutically acceptable salt
Dose	A therapeutically effective amount

A generic product would create the greatest infringement risk if its approved label instructs use of telotristat ethyl for a disease mediated by peripheral serotonin and the product contains the claimed crystalline form or salt.

The claim is narrower than a claim to telotristat ethyl generally. An accused product could contest infringement by arguing that it contains a different polymorph, an amorphous form, a different salt, or a material that does not satisfy the claim's crystalline-form limitations. That defense would depend on solid-state characterization and the precise product supplied to the market.

Which diseases are covered by US Patent 8,653,094?

Claims 2 through 5 identify specific disease categories:

Claim	Covered disease or disorder
2	Carcinoid syndrome
3	Gastrointestinal disease or disorder
4	Irritable bowel syndrome
5	Crohn's disease

Claim 2 is the most commercially significant because Xermelo is approved for carcinoid syndrome diarrhea inadequately controlled by somatostatin analog therapy. The broader wording in claim 1 may reach other diseases if the patentee can establish that peripheral serotonin mediates the disease and the other claim limitations are satisfied.

Claims 3 through 5 do not necessarily expand the compound scope. They narrow the disease limitation to specified gastrointestinal conditions.

How do claims 6 through 9 protect the crystalline free-base form?

Claims 6 through 9 identify the crystalline free base and define it by physical characteristics.

Claim 6

Claim 6 covers crystalline telotristat ethyl in the free-base form.

Claim 7

Claim 7 adds a melting point of about 104°C. The term "about" provides some tolerance around the stated value, but the effective range would depend on analytical method, sample preparation, heating rate, purity, and claim construction.

Claim 8

Claim 8 identifies one or more X-ray powder diffraction peaks at approximately:

10.7 degrees 2θ
12.2 degrees 2θ
12.8 degrees 2θ
17.7 degrees 2θ
22.0 degrees 2θ

The claim does not require every listed peak. It requires one or more of the identified peaks.

Claim 9

Claim 9 requires an X-ray powder diffraction pattern substantially the same as the pattern shown in Figure 1. This is a pattern-comparison claim. In a dispute, the parties would likely compare reference and accused samples using powder X-ray diffraction, with attention to peak position, intensity, instrument conditions, and sample preparation.

How do claims 10 through 18 protect telotristat salts?

Claims 10 through 18 cover crystalline salt forms.

Claims	Salt or analytical limitation
10	Crystalline pharmaceutically acceptable salt
11-15	Hippurate salt
16-18	Succinate salt

Hippurate salt claims

Claims 11 through 15 cover crystalline telotristat ethyl hippurate.

The specified characteristics are:

Melting point of about 145°C under claim 12
X-ray powder diffraction peaks at approximately 8.2, 9.5, 12.6, 16.9, 21.8, 22.0, 22.7, 24.3 and/or 29.1 degrees 2θ under claim 13
A powder diffraction pattern substantially the same as Figure 2 under claim 14
A Raman spectrum substantially the same as Figure 3 under claim 15

These claims create multiple routes to infringement. A product may fall within the claim based on salt identity, thermal behavior, X-ray diffraction, or Raman comparison, depending on the asserted claim.

Succinate salt claims

Claims 16 through 18 cover crystalline telotristat ethyl succinate.

Claim 17 identifies peaks at approximately:

7.7 degrees 2θ
11.5 degrees 2θ
11.7 degrees 2θ
15.7 degrees 2θ
17.9 degrees 2θ
21.1 degrees 2θ
23.2 degrees 2θ

Claim 18 requires a pattern substantially the same as Figure 4.

The hippurate and succinate claims are alternative salt protections. A generic manufacturer that avoids the hippurate salt could still face risk if it uses the claimed succinate form and markets it for a covered indication.

Is US Patent 8,653,094 a formulation patent?

It is a solid-state and therapeutic-use patent, not a conventional finished-dosage-form patent.

The patent protects:

Crystalline telotristat ethyl
Crystalline telotristat ethyl hippurate
Crystalline telotristat ethyl succinate
Certain X-ray diffraction patterns
A Raman spectrum for the hippurate
Use of the claimed forms to treat peripheral-serotonin-mediated diseases

The patent does not, based on the supplied claims, protect:

A particular tablet coating
A specific excipient combination
A tablet disintegration profile
A controlled-release system
A capsule shell
A manufacturing apparatus
A broad pharmaceutical composition containing any telotristat form
A method of synthesizing telotristat ethyl

A generic manufacturer may therefore need to evaluate both active-ingredient solid-state patents and any separate patents covering tablets, processes, formulations, or therapeutic regimens.

When does US Patent 8,653,094 expire?

The patent has a nominal statutory term tied to its earliest effective US nonprovisional filing date. Public patent records identify the relevant filing and priority chain as beginning in January 2010 or January 2011, depending on the specific continuity and priority record used for term calculation.

For practical Orange Book and freedom-to-operate analysis, the patent should be treated as having a nominal expiration in approximately January 2031, subject to:

Patent-term adjustment
Patent-term extension, if granted
Terminal disclaimers
Continuation or divisional relationships
The exact USPTO term calculation
Any later disclaimer or correction

The patent was granted on February 18, 2014. Grant timing does not determine expiration for a modern US utility patent; the filing and priority chain controls the term. (United States Patent and Trademark Office, 2024a)

What is the Orange Book status of US Patent 8,653,094?

US Patent 8,653,094 is associated with the Xermelo telotristat ethyl product patent estate and is relevant to FDA generic approval timing. Orange Book significance depends on whether the patent is listed for the specific reference product, the listed use code, and the status of the product's regulatory exclusivity.

The principal reference product is Xermelo, approved by FDA on February 28, 2017, for adults with carcinoid syndrome diarrhea inadequately controlled by short-acting octreotide or lanreotide. (FDA, 2017)

The patent's method-of-use scope is aligned with the approved carcinoid syndrome indication, particularly claim 2. A generic applicant seeking approval for a corresponding indication would normally need to address listed patents through:

Paragraph IV certification
A section viii statement carving out a patented use
Or a Paragraph III certification agreeing to wait until expiration

The commercial impact depends on the Orange Book-listed expiration date and use code in force when an ANDA is submitted. Patent 8,653,094 should not be analyzed in isolation from the other listed Xermelo patents.

What FDA exclusivity protected Xermelo?

Xermelo received new chemical entity exclusivity. The five-year NCE period generally prevented submission of an ANDA or 505(b)(2) application containing the same active moiety until February 28, 2022, subject to the statutory rules governing submission and patent certifications.

NCE exclusivity is separate from patent protection. Its end did not eliminate the approximately 2031 patent barrier associated with US Patent 8,653,094 or other Xermelo patents.

Milestone	Date
FDA approval of Xermelo	February 28, 2017
Approximate end of five-year NCE exclusivity	February 28, 2022
Approximate nominal expiration of US 8,653,094	January 2031
FDA-approved indication	Carcinoid syndrome diarrhea inadequately controlled by somatostatin analog therapy

What Paragraph IV risks apply to a telotristat generic?

A Paragraph IV challenger would likely focus on one or more of five positions:

Non-infringement: The proposed product uses a nonclaimed polymorph, amorphous material, or different salt.
Invalidity for anticipation: An earlier reference allegedly discloses the claimed crystalline form or the relevant physical characteristics.
Invalidity for obviousness: The challenger argues that crystallization, salt selection, or characterization would have been routine.
Indefiniteness: The challenger attacks terms such as "about" or "substantially the same."
Lack of enablement or written description: The challenger argues that the claims extend beyond what the patent adequately describes.

The strongest non-infringement pathway would usually involve avoiding the claimed solid form. That approach is technically difficult because the marketed product must remain chemically and physically suitable for manufacture, stability testing, dissolution, bioequivalence, and regulatory approval.

The strongest invalidity issues would likely concern whether the specific polymorph or salt form was disclosed or predictable before the patent's priority date. Physical-form claims often turn on the quality of comparative analytical data rather than on chemical identity alone.

Does the patent cover the Xermelo hippurate product?

The hippurate claims are commercially important because telotristat etiprate is the hippurate salt associated with Xermelo regulatory and commercial materials.

If the reference product contains the claimed crystalline hippurate form, claims 10 through 15 may create direct product-use infringement exposure for a generic product using the same form. Claims 11 through 15 are narrower than claim 10 because they require the hippurate salt and, in some cases, specified physical or spectroscopic characteristics.

The exact infringement analysis would require testing the generic's active ingredient and comparing it with the claimed form. Chemical equivalence alone would not automatically establish infringement of every polymorph-dependent claim.

Which companies own and commercialize the relevant rights?

Role	Company
Original developer and US commercial rights holder	Lexicon Pharmaceuticals, Inc.
International commercialization partner	Ipsen
Reference product	Xermelo
Active ingredient	Telotristat ethyl, marketed in the etiprate/hippurate form
Regulatory pathway for potential competitors	ANDA or, depending on product and strategy, 505(b)(2)

Lexicon entered into a commercialization agreement with Ipsen covering telotristat outside the United States. The rights structure affects royalty flows and international patent enforcement but does not change the territorial scope of US Patent 8,653,094. (Lexicon Pharmaceuticals, Inc., 2023)

How strong is the patent estate for telotristat?

US Patent 8,653,094 is moderately strong against a copycat product that uses the same crystalline hippurate or succinate form and the labeled carcinoid syndrome indication.

Its strength is based on:

Exact stereochemical definition of the active molecule
Explicit crystalline-form limitations
Salt-specific claims
X-ray diffraction markers
A Raman marker for the hippurate form
A method-of-use claim corresponding to the approved indication

Its limits are equally material:

It does not claim every telotristat formulation.
It does not necessarily block a different solid form.
It does not claim all uses of telotristat ethyl without the peripheral-serotonin limitation.
It does not independently establish infringement by chemical identity alone.
The patent's term is finite and approximately reaches 2031.

The broader commercial estate may include separate compound, use, formulation, process, and continuation patents. Those patents should be mapped separately because a generic may avoid one patent while remaining blocked by another.

What patent litigation and settlement risks affect generic entry?

A Paragraph IV filing could trigger a Hatch-Waxman action under 35 U.S.C. §271(e)(2). If the NDA holder sues within the statutory period, FDA approval may be subject to a 30-month stay, unless the litigation is resolved earlier or the stay is modified.

Relevant dispute issues would include:

Whether the ANDA product contains the claimed crystalline form
Whether the proposed label induces use for carcinoid syndrome
Whether the patent claims are invalid over prior-art solid forms
Whether the Orange Book use code properly corresponds to the claim scope
Whether the applicant can carve out patented uses
Whether a settlement permits an authorized generic or delayed launch

No settlement terms should be assumed from the patent record alone. A settlement may preserve a patent's commercial value even if the patent is vulnerable in litigation.

What generic launch scenarios exist?

At-risk launch before patent expiration

A generic could launch before January 2031 if it receives approval after litigation success, a favorable settlement, or a court ruling that removes the relevant barrier. An at-risk launch could expose the applicant to damages and injunctive relief.

Label carve-out

A section viii strategy may be available if the applicant removes patented indications from its labeling. This approach is less useful where the principal commercial indication is the patented carcinoid syndrome use.

Alternative solid form

A generic could attempt to use a nonclaimed polymorph, amorphous form, or different salt. That strategy would require robust evidence that the commercial material does not meet the X-ray, melting-point, Raman, or salt limitations.

Delayed launch

The lowest litigation-risk route is launch after expiration of the relevant listed patents, subject to any later-issued patents and regulatory requirements.

Does biosimilar risk apply to Xermelo?

No. Xermelo is a small-molecule drug, not a biologic. Biosimilar provisions under the Biologics Price Competition and Innovation Act do not apply.

Competitive entry would proceed through the generic-drug framework, principally an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The relevant competitive threats are generic telotristat products, not biosimilars.

What is the geographic coverage of US Patent 8,653,094?

The patent provides protection only in the United States. Foreign counterparts may protect telotristat crystalline forms or uses in Europe, Japan, Canada, Australia, and other jurisdictions, but each counterpart has its own:

Claim scope
Priority record
Validity status
Patent-term calculation
Litigation history
Regulatory linkage rules

The US patent cannot block manufacture, sale, or use solely outside the United States unless another jurisdiction's patent rights apply.

Key Takeaways

US Patent 8,653,094 is a crystalline-form and method-of-treatment patent for telotristat ethyl.
It covers the crystalline free base and crystalline hippurate and succinate salts.
Claims 2 through 5 target carcinoid syndrome and gastrointestinal diseases, including irritable bowel syndrome and Crohn's disease.
The hippurate claims are especially relevant to Xermelo/telotristat etiprate.
The patent uses melting point, X-ray diffraction, and Raman-spectroscopy limitations to define solid forms.
It is not a conventional tablet-excipient or controlled-release formulation patent.
Its nominal US expiration is approximately January 2031, subject to the official USPTO term calculation and any adjustment.
Generic risk centers on solid-form identity, method-of-use labeling, Paragraph IV certification, and potential Hatch-Waxman litigation.
Biosimilar competition is irrelevant because telotristat ethyl is a small molecule.
A complete launch assessment requires reviewing this patent with the full Xermelo Orange Book estate and any later-issued continuation or formulation patents.

FAQs

What is the active ingredient protected by US Patent 8,653,094?

The patent protects crystalline forms and salts of telotristat ethyl, including crystalline telotristat ethyl hippurate and succinate.

Does US Patent 8,653,094 cover telotristat hydrochloride?

The supplied claims do not specifically identify a hydrochloride salt. Claim 10 uses the broader phrase "pharmaceutically acceptable salt," but claims 11 through 18 focus on hippurate and succinate salts. Whether a hydrochloride product falls within claim 10 would depend on claim construction and the required crystalline characteristics.

Can a generic avoid the patent by using an amorphous telotristat form?

Potentially, but only if the product does not meet the patent's crystalline-form limitations and does not otherwise infringe an asserted claim. Amorphous-form development would require separate regulatory, stability, manufacturing, and bioequivalence validation.

Is telotristat etiprate the same as telotristat ethyl?

Telotristat etiprate is the hippurate salt form associated with telotristat ethyl. Regulatory and commercial references may use the terms differently depending on whether they identify the active moiety, ester compound, or salt form.

What is the main legal weakness of US Patent 8,653,094?

The principal vulnerability is its dependence on specific solid-state and analytical characteristics. A challenger may argue that the accused product uses a different form or that the claimed form was anticipated, obvious, insufficiently described, or defined with inadequate precision.

References

Lexicon Pharmaceuticals, Inc. (2014). U.S. Patent No. 8,653,094: Methods of treating or managing diseases or disorders mediated by peripheral serotonin. United States Patent and Trademark Office. https://patents.google.com/patent/US8653094
U.S. Food and Drug Administration. (2017, February 28). Xermelo approval letter. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/208794Orig1s000ltr.pdf
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (2017). Xermelo prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208794s000lbl.pdf
United States Patent and Trademark Office. (2024a). Patent term adjustment. https://www.uspto.gov/patents/laws/patent-term-adjustment
Lexicon Pharmaceuticals, Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission. https://www.sec.gov/edgar/browse/?CIK=1062822

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Tersera	XERMELO	telotristat etiprate	TABLET;ORAL	208794-001	Feb 28, 2017		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				THE TREATMENT OF CARCINOID SYNDROME DIARRHEA IN COMBINATION WITH SOMATOSTATIN ANALOG (SSA) THERAPY IN ADULTS INADEQUATELY CONTROLLED BY SSA THERAPY	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	068558	⤷ Start Trial
Australia	2008304439	⤷ Start Trial
Brazil	PI0817270	⤷ Start Trial
Canada	2700835	⤷ Start Trial
Chile	2008002880	⤷ Start Trial
China	101809018	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 8,653,094